RxDoctor Payments Data

William von Almen, MD

Gynecology · New Orleans, LANPI 1831123876

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $13,050 of the $16,940 with a category attached, or 77.0%. 33 manufacturers reported payments, led by Organon at 41.4% of the total. Reporting peaked in 2019 at $5,944 and has fallen 98.1% since, to $111 in 2025. Among gynecology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$16,940in general payments, 2019–2025

Across 139 payments — averaging $121.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organon$7K
  • Merck$6K
  • Applied Medical Resources Corporation$991
  • AbbVie$691
  • Amgen$359
  • Biohaven Pharmaceuticals, Inc.$273
  • plus $1K from 27 others

What the payments were for

  • Consulting fees$250%
  • Speaking & faculty fees$13,05077%
  • Travel & lodging$9576%
  • Food & beverage$2,85617%
  • Education$520%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,940 in reported general payments places this provider in the 90th percentile of 37 gynecology providers in Louisiana.

See all gynecology providers in Louisiana

Medicare billing

Part B allowed, 2024
$6,448
Medicare patients
93
Services billed
161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PremproEstrogen,con/M-Progest Acet31$7,975
PremarinEstrogens, Conjugated13$5,652
Estradiol174$4,654
Estradiol (Once Weekly)Estradiol22$2,553
Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet26$2,075
Estradiol (Twice Weekly)Estradiol14$1,967
Raloxifene Hcl57$1,341
ValacyclovirValacyclovir Hcl14$933
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine28$907
ProgesteroneProgesterone, Micronized17$557
Alendronate Sodium41$375
Clobetasol Propionate18$359
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst19$261
Medroxyprogesterone Acetate20$186
Clonazepam15$175

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPrempro, Premarin$160$13,62744 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 37 gynecology providers in Louisiana.

Other gynecology in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →